Premium
Pharmacokinetics of a continuous rate infusion of ceftiofur sodium in normal foals
Author(s) -
WEARN J. M. G.,
DAVIS J. L.,
HODGSON D. R.,
RAFFETTO J. A.,
CRISMAN M. V.
Publication year - 2013
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.2012.01403.x
Subject(s) - veterinary medicine , medicine , library science , computer science
[Extract] Systemic bacterial infection, resulting in bacterial sepsis and systemic inflammatory response syndrome, is the primary cause of equine neonatal morbidity and mortality (Cohen, 1994; Hollis et al., 2008). Ceftiofur sodium (CS), a third-generation cephalosporin antimicrobial, has in vitro efficacy against many bacterial organisms cultured from septicemic equine neonates (Jaglan et al., 1994; Marsh & Palmer, 2001; Sanchez et al., 2008; Meyer et al., 2009).\ud\udCeftiofur sodium is a time-dependent, bactericidal, β-lactam antimicrobial (Owens & Ambrose, 2007). To optimize the likelihood of efficacy, dosing regimens are designed to maximize the duration concentrations of antimicrobial at the site of infection are greater than the MIC of the pathogen (Turnidge, 1998). For gram-positive organisms, CS has a period of post-antibiotic effect and post-antibiotic leukocyte enhancement. For gram-negative organisms no post-antibiotic effect exists and reduced efficacy of cephalosporin antimicrobial therapy has been reported when T > MIC is <80% (Craig, 2002). In neutropenic patients, maintaining T > MIC for 90–100% of the dosing interval is recommended (Turnidge, 1998)